Developer docs
API playgroundTry for free, no card

Search company profiles

Applied StemCell

Full company profile

uuid0000dnd

Namestring
Applied StemCell
Legal namestring
Applied StemCell, Inc.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Applied StemCell, Inc. is a privately held biotechnology company founded in 2008 and headquartered in Milpitas, California, that builds genome engineering and induced pluripotent stem cell (iPSC) platforms for drug discovery and cell therapy development. Its core technology is TARGATT™, a proprietary serine integrase-based site-specific integration system that inserts large DNA payloads (up to 50 kb at ~88% efficiency) into the H11 safe harbor locus in mammalian cells, complementing in-house CRISPR/Cas9 and MAD7 gene editing capabilities and a hypoimmunogenic iPSC platform (B2M/CIITA double knock-out). The company also operates five ISO 7 GMP cleanrooms with ISO 5 workspaces, holding ISO 13485 certification, California Department of Public Health licensure, and an FDA Drug Master File for its GMP-grade iPSC cell line ASE-9280.

Applied StemCell monetizes across a hybrid product-and-services model: catalog sales of TARGATT knock-in kits (RUO and GMP grades) for hiPSCs, HEK293, and CHO cells, plus ActiCells™ hiPSC lines and iPSC-derived differentiated cells (neurons, cardiomyocytes, NK cells, microglia, retinal cells, photoreceptors) priced at $1,650–$3,080 per unit; and quote-based professional services spanning iPSC generation (>95% reprogramming success), genome engineering, differentiation, cGMP cell banking, process and analytical development, and end-to-end clinical manufacturing. It sells research-grade products globally through direct sales and a distributor network covering Europe (Germany, Austria, Belgium, Bulgaria, Croatia, others) and Asia (China), while GMP services and custom projects are handled through direct enterprise engagement.

The customer base targets biopharma companies developing cell and gene therapies and academic researchers using iPSC platforms for disease modeling and drug discovery. Recent activity — including a new CEO (Dolores Baksh, August 2025), a Director of Business Development hire (September 2025), a strategic partnership with Cellipont Bioservices for integrated therapy development services (March 2026), an FDA Drug Master File submission (April 2025), and a 50 kb knock-in technical demonstration (November 2025) — indicates the company is positioning to scale its clinical-grade and contract manufacturing business beyond its historical research-catalog base.

Short descriptiontext

Applied StemCell is a Milpitas-based biotechnology company that develops TARGATT-based genome engineering tools, iPSC lines and differentiated cells, and GMP cell therapy manufacturing services for biopharma developers and academic researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMilpitas, United States
HQ citystring
Milpitas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC cell engineering, genome editing services, cGMP cell manufacturing, knock-in cell therapy, induced pluripotent stem cells
Industry5 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Cell therapy and genome engineering services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1TARGATT Knock-in Kits
TypeOne Time License
Description

Sale of research-use-only and GMP-grade TARGATT kit products including hiPSC, HEK293, and CHO cell kits with landing pad cell lines, donor plasmids, and integrase plasmids. Kits are sold with license requirements for commercial use and MTA for academic use.

appliedstemcell.com
2iPSC Products
TypeOne Time License
Description

Sale of iPSC lines, iPSC-derived cells (neurons, cardiomyocytes, NK cells, etc.), and GMP-grade iPSCs. Products include catalog items priced at $1,650-$3,080 for differentiated cells.

appliedstemcell.com
3Genome Engineering Services
TypeProfessional Services
Description

Custom cell line engineering services including knock-in, knock-out, point mutations using CRISPR, MAD7, and TARGATT technologies. Services offered at research or GMP grade with deliverables in 6-8 weeks for in-house lines.

appliedstemcell.com
4iPSC Services
TypeProfessional Services
Description

iPSC generation, gene editing, and differentiation services. Includes GMP reprogramming, differentiation into various lineages (neural, cardiac, immune cells). Services provided from California facilities.

appliedstemcell.com
5cGMP Manufacturing Services
TypeManaged Services
Description

Complete GMP cell therapy manufacturing including cell banking, scale-up, fill/finish, and quality testing. Services span from technology transfer through clinical supply for cell and gene therapy products.

appliedstemcell.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details5 tiers
1iPSC-Derived Cells - Standard cell types
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,650 for most cell types including microglia, motor neurons, cortical neurons, dopaminergic neurons, astrocytes, cardiomyocytes, monocytes, endothelial cells, and retinal pigment epithelium cells. $1,980 for myoblasts. $2,200 for photoreceptor progenitor cells.

appliedstemcell.com
2iPSC-Derived NK Cells
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,980 - $3,080 depending on differentiation stage and quantity requirements.

appliedstemcell.com
3iPSC-Derived Hematopoietic Progenitor Cells
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$2,200 per unit.

appliedstemcell.com
4TARGATT Kits and GMP Products
ModelOtherBilling cadencePay-as-you-go
Notes

Products require inquiry/quote. Commercial use requires license; academic use requires MTA.

appliedstemcell.com
5Custom Cell Line Engineering Services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing following consultation with technical team. Projects range from 6-8 weeks with in-house lines to 2-3 months with customer-provided cells.

appliedstemcell.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1TARGATT™
Description

Proprietary large knock-in technology platform for site-specific integration of large DNA fragments (up to 50 kb) into mammalian genomes at the H11 safe harbor locus.

appliedstemcell.com
+3 more records
Core offering1 text field

Applied StemCell develops and sells proprietary genome engineering products and services centered on its TARGATT™ site-specific knock-in technology, supplemented by CRISPR/Cas9 and MAD7 platforms. The company manufactures and distributes TARGATT™ knock-in kits (RUO and GMP grades), ActiCells™ iPSC lines, iPSC-derived differentiated cells, and hiEX™ research exosomes, and provides custom cell line engineering, iPSC generation/editing/differentiation, and cGMP cell banking and manufacturing services to biopharma and academic customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • ~88% targeted integration efficiency for 50 kb constructs in iPSCs
+4 more records
Product overview1 text field

Applied StemCell is a genome engineering platform company offering an integrated portfolio of products and services for cell therapy development. The core offering centers on TARGATT™ technology, a proprietary site-specific serine integrase system enabling large DNA knock-ins (up to 50 kb) at the H11 safe harbor locus. Product portfolio includes TARGATT™-enabled knock-in kits for hiPSCs (RUO and GMP grades), HEK293 cells, and CHO cells; ActiCells™ GMP-grade and RUO hiPSC lines; hiEX™ Research iPSC Exosomes; and iPSC-derived differentiated cells (neurons, cardiomyocytes, NK cells, microglia, retinal cells, and more). Services span the full development pathway from iPSC generation, genome engineering (TARGATT™, CRISPR/Cas9, MAD7), and differentiation, through GMP cell banking and manufacturing, with regulatory/quality management support. The company operates cGMP-compliant cleanroom facilities in Milpitas, California.

Product and service17 records
1TARGATT™ RUO Hypo hiPSC Knock-in Kit
CategoryResearch Product
Description

Research-use-only hypoimmunogenic hiPSC platform pre-built with TARGATT technology, featuring B2M/CIITA double knock-out for allogeneic cell therapy development with up to 20 kb knock-in capacity. Targeted at academic and biopharma researchers building allogeneic cell therapy candidates.

2TARGATT™ RUO hiPSC Knock-in Kit
CategoryResearch Product
Description

Research-use-only hiPSC line engineered with TARGATT landing pad at the H11 locus, enabling site-specific single-copy insertion of up to 20 kb DNA payloads for cell therapy development.

3TARGATT™ GMP hiPSC Knock-in Kit
CategoryGMP Product
Description

Clinical-grade GMP hiPSC line with TARGATT landing pad, backed by US FDA Drug Master File, supporting site-specific integration of up to 20 kb for IND-enabling studies and clinical-grade cell therapy programs.

4TARGATT™ HEK293 Kits
CategoryResearch Product
Description

HEK293 cell lines with TARGATT landing pad for efficient protein expression and library creation, achieving up to 80% integration efficiency without drug selection.

5TARGATT™ CHO Kits
CategoryResearch Product
Description

CHO K1 cell lines with TARGATT landing pads at H11 and A2 sites for mammalian protein and antibody expression, and high-throughput library screening.

6ActiCells™ GMP hiPSCs
CategoryGMP Product
Description

GMP-grade human iPSCs reprogrammed from CD34+ cord blood cells with proven gene editing and differentiation capabilities, covered by a US FDA Drug Master File.

7ActiCells™ RUO hiPSCs
CategoryResearch Product
Description

Research-use-only human iPSCs reprogrammed from CD34+ cord blood cells, matching the GMP line for preclinical development.

8hiEX™ Research iPSC Exosomes
CategoryResearch Product
Description

Research-use exosomes derived from iPSCs for regenerative medicine research in wound healing, aging, and neural regeneration applications.

9iPSC-Derived Cells
CategoryResearch Product
Description

Differentiated cell types including neurons, cardiomyocytes, NK cells, microglia, and retinal cells derived from iPSCs for research applications, with published unit pricing of $1,650-$3,080.

10Genome Engineering Services
CategoryService
Description

Custom mammalian cell line development services using TARGATT™, CRISPR/Cas9, and MAD7 technologies for knock-in, knock-out, and point mutations, with 6-8 week turnaround for in-house lines and 2-3 months for customer-provided cells.

11iPSC Gene Editing Services
CategoryService
Description

Specialized iPSC genome editing services with pluripotency maintenance, offering knock-ins, gene fusions, conditional expression, and overexpression capabilities.

12iPSC Differentiation Services
CategoryService
Description

Differentiation of iPSCs into neural, hematopoietic, cardiovascular, and other lineages including neurons, NK cells, and cardiomyocytes.

13iPSC Generation Services
CategoryService
Description

Reprogramming services converting somatic cells to iPSCs using episomal, Sendai virus, or retroviral methods with >95% success rate.

14cGMP Cell Banking Services
CategoryService
Description

Master and working cell bank generation under GMP conditions with customizable bank size, concentration, and quality testing.

15cGMP Cell Manufacturing Services
CategoryService
Description

End-to-end GMP cell therapy manufacturing including iPSC engineering, differentiation, fill-finish, and clinical drug substance production.

16Process and Analytical Development
CategoryService
Description

CMC development services including gap assessment, process optimization, and analytical method qualification for cell therapy products.

17Quality Management and Regulatory Services
CategoryService
Description

QA/QC and regulatory consulting for cell and gene therapy including IND/BLA preparation, FDA compliance, and ISO 13485 quality systems.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Strategic partnership combining Applied StemCell's GMP iPSC lines and TARGATT gene editing technology with Cellipont's cGMP manufacturing and regulatory expertise. The collaboration provides integrated iPSC-derived cell therapy development services designed to reduce technical risk and shorten development timelines by connecting upstream cell engineering with late-stage manufacturing execution. Intended to support therapy developers from early development through clinical and commercial-scale production.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading supplier of iPSC-derived differentiated cells (neurons, cardiomyocytes, hepatocytes) for drug discovery and cell therapy. Directly comparable to Applied StemCell's ActiCells and iPSC-derived cell catalog, with overlapping products, pricing models, and academic/biopharma customer base.

TypeDirect peer
Description

Provides iPSC reprogramming services, iPSC-derived cells, and gene-editing reagents for drug discovery and regenerative medicine. Highly comparable to Applied StemCell's iPSC services and product portfolio across research and GMP-grade workflows.

TypeDirect peer
Description

Cell therapy-focused CDMO offering cGMP manufacturing, cell banking, and regulatory services. Now an integrated partner of Applied StemCell; directly comparable for the GMP iPSC manufacturing and cell therapy CDMO services Applied StemCell delivers.

TypeEmerging player
Description

Clinical-stage developer of iPSC-derived allogeneic cell therapies (NK and T cells) using multi-gene engineering. Comparable in its reliance on iPSC engineering, knock-in platforms, and hypoimmunogenic design — a downstream customer and technology benchmark for Applied StemCell.

TypeEmerging player
Description

iPSC-derived NK and T cell therapy developer using multiplexed gene editing. Comparable end-user of site-specific knock-in and large-payload integration, and a natural customer for Applied StemCell's TARGATT platform.

TypeEmerging player
Description

Developer of iPSC-derived cell products (ioCells) using opti-ox technology for reprogramming and differentiation. Comparable in offering catalog iPSC-derived cells to research and therapeutic customers, overlapping with Applied StemCell's iPSC-derived cell business.

7Takara Bio
TypeDirect peer
Description

Provides cell biology reagents, gene editing tools, and iPSC-related products including the Cellartis line. Comparable product portfolio for stem cell and gene editing research tools, serving the same academic and biopharma customers.

TypeEmerging player
Description

Specialty CDMO focused on lentiviral and AAV gene therapy manufacturing, with emerging cell therapy capabilities. Comparable to Applied StemCell's cGMP manufacturing services for gene-modified cell therapies, particularly in early-phase clinical supply.

TypeBroad incumbent
Description

One of the largest global CDMOs offering iPSC-derived cell therapy manufacturing, viral vector production, and process development. Overlaps with Applied StemCell's GMP iPSC and cell therapy CDMO offering as a much larger incumbent competitor.

TypeBroad incumbent
Description

Major CRO/CDMO with cell and gene therapy manufacturing services (via Cobra Biologics and Cellular Therapy & Innovation Center). Competes with Applied StemCell's GMP cell banking and manufacturing services as a large-scale, full-service alternative.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Applied StemCell

Cell therapy and genome engineering servicesappliedstemcell.com

Applied StemCell is a Milpitas-based biotechnology company that develops TARGATT-based genome engineering tools, iPSC lines and differentiated cells, and GMP cell therapy manufacturing services for biopharma developers and academic researchers.

What Applied StemCell does

Applied StemCell, Inc. is a privately held biotechnology company founded in 2008 and headquartered in Milpitas, California, that builds genome engineering and induced pluripotent stem cell (iPSC) platforms for drug discovery and cell therapy development. Its core technology is TARGATT™, a proprietary serine integrase-based site-specific integration system that inserts large DNA payloads (up to 50 kb at ~88% efficiency) into the H11 safe harbor locus in mammalian cells, complementing in-house CRISPR/Cas9 and MAD7 gene editing capabilities and a hypoimmunogenic iPSC platform (B2M/CIITA double knock-out). The company also operates five ISO 7 GMP cleanrooms with ISO 5 workspaces, holding ISO 13485 certification, California Department of Public Health licensure, and an FDA Drug Master File for its GMP-grade iPSC cell line ASE-9280.

Applied StemCell monetizes across a hybrid product-and-services model: catalog sales of TARGATT knock-in kits (RUO and GMP grades) for hiPSCs, HEK293, and CHO cells, plus ActiCells™ hiPSC lines and iPSC-derived differentiated cells (neurons, cardiomyocytes, NK cells, microglia, retinal cells, photoreceptors) priced at $1,650–$3,080 per unit; and quote-based professional services spanning iPSC generation (>95% reprogramming success), genome engineering, differentiation, cGMP cell banking, process and analytical development, and end-to-end clinical manufacturing. It sells research-grade products globally through direct sales and a distributor network covering Europe (Germany, Austria, Belgium, Bulgaria, Croatia, others) and Asia (China), while GMP services and custom projects are handled through direct enterprise engagement.

The customer base targets biopharma companies developing cell and gene therapies and academic researchers using iPSC platforms for disease modeling and drug discovery. Recent activity — including a new CEO (Dolores Baksh, August 2025), a Director of Business Development hire (September 2025), a strategic partnership with Cellipont Bioservices for integrated therapy development services (March 2026), an FDA Drug Master File submission (April 2025), and a 50 kb knock-in technical demonstration (November 2025) — indicates the company is positioning to scale its clinical-grade and contract manufacturing business beyond its historical research-catalog base.

Applied StemCell firmographics

Firmographics
Name
Applied StemCell
Legal name
Applied StemCell, Inc.
Website
https://appliedstemcell.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Applied StemCell is a Milpitas-based biotechnology company that develops TARGATT-based genome engineering tools, iPSC lines and differentiated cells, and GMP cell therapy manufacturing services for biopharma developers and academic researchers.
Ownership category
akta.pro rank

Applied StemCell industry classification

Industry
Product category
Cell therapy and genome engineering services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • IPSC cell engineering
  • Genome editing services
  • CGMP cell manufacturing
  • Knock-in cell therapy
  • Induced pluripotent stem cells

Where Applied StemCell is headquartered

Location

Headquarters

HQ city
Milpitas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Applied StemCell business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. TARGATT Knock-in Kits: Sale of research-use-only and GMP-grade TARGATT kit products including hiPSC, HEK293, and CHO cell kits with landing pad cell lines, donor plasmids, and integrase plasmids. Kits are sold with license requirements for commercial use and MTA for academic use.
  2. iPSC Products: Sale of iPSC lines, iPSC-derived cells (neurons, cardiomyocytes, NK cells, etc.), and GMP-grade iPSCs. Products include catalog items priced at $1,650-$3,080 for differentiated cells.
  3. Genome Engineering Services: Custom cell line engineering services including knock-in, knock-out, point mutations using CRISPR, MAD7, and TARGATT technologies. Services offered at research or GMP grade with deliverables in 6-8 weeks for in-house lines.
  4. iPSC Services: iPSC generation, gene editing, and differentiation services. Includes GMP reprogramming, differentiation into various lineages (neural, cardiac, immune cells). Services provided from California facilities.
  5. cGMP Manufacturing Services: Complete GMP cell therapy manufacturing including cell banking, scale-up, fill/finish, and quality testing. Services span from technology transfer through clinical supply for cell and gene therapy products.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goiPSC-Derived Cells - Standard cell types
Unit PricingPay-as-you-goiPSC-Derived NK Cells
Unit PricingPay-as-you-goiPSC-Derived Hematopoietic Progenitor Cells
OtherPay-as-you-goTARGATT Kits and GMP Products
OtherMulti-year contractCustom Cell Line Engineering Services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Applied StemCell product offering

Product offering

Core offering

Applied StemCell develops and sells proprietary genome engineering products and services centered on its TARGATT™ site-specific knock-in technology, supplemented by CRISPR/Cas9 and MAD7 platforms. The company manufactures and distributes TARGATT™ knock-in kits (RUO and GMP grades), ActiCells™ iPSC lines, iPSC-derived differentiated cells, and hiEX™ research exosomes, and provides custom cell line engineering, iPSC generation/editing/differentiation, and cGMP cell banking and manufacturing services to biopharma and academic customers.

Product overview

Applied StemCell is a genome engineering platform company offering an integrated portfolio of products and services for cell therapy development. The core offering centers on TARGATT™ technology, a proprietary site-specific serine integrase system enabling large DNA knock-ins (up to 50 kb) at the H11 safe harbor locus. Product portfolio includes TARGATT™-enabled knock-in kits for hiPSCs (RUO and GMP grades), HEK293 cells, and CHO cells; ActiCells™ GMP-grade and RUO hiPSC lines; hiEX™ Research iPSC Exosomes; and iPSC-derived differentiated cells (neurons, cardiomyocytes, NK cells, microglia, retinal cells, and more). Services span the full development pathway from iPSC generation, genome engineering (TARGATT™, CRISPR/Cas9, MAD7), and differentiation, through GMP cell banking and manufacturing, with regulatory/quality management support. The company operates cGMP-compliant cleanroom facilities in Milpitas, California.

Differentiator

Problem solved

Functional benefit

Brands

  • TARGATT™: Proprietary large knock-in technology platform for site-specific integration of large DNA fragments (up to 50 kb) into mammalian genomes at the H11 safe harbor locus.
  • ActiCells™
  • hiEX™
  • ActiCells™ GMP hiPSCs

Products and services

  • TARGATT™ RUO Hypo hiPSC Knock-in Kit Research-use-only hypoimmunogenic hiPSC platform pre-built with TARGATT technology, featuring B2M/CIITA double knock-out for allogeneic cell therapy development with up to 20 kb knock-in capacity. Targeted at academic and biopharma researchers building allogeneic cell therapy candidates.
  • TARGATT™ RUO hiPSC Knock-in Kit Research-use-only hiPSC line engineered with TARGATT landing pad at the H11 locus, enabling site-specific single-copy insertion of up to 20 kb DNA payloads for cell therapy development.
  • TARGATT™ GMP hiPSC Knock-in Kit Clinical-grade GMP hiPSC line with TARGATT landing pad, backed by US FDA Drug Master File, supporting site-specific integration of up to 20 kb for IND-enabling studies and clinical-grade cell therapy programs.
  • TARGATT™ HEK293 Kits HEK293 cell lines with TARGATT landing pad for efficient protein expression and library creation, achieving up to 80% integration efficiency without drug selection.
  • TARGATT™ CHO Kits CHO K1 cell lines with TARGATT landing pads at H11 and A2 sites for mammalian protein and antibody expression, and high-throughput library screening.
  • ActiCells™ GMP hiPSCs GMP-grade human iPSCs reprogrammed from CD34+ cord blood cells with proven gene editing and differentiation capabilities, covered by a US FDA Drug Master File.
  • ActiCells™ RUO hiPSCs Research-use-only human iPSCs reprogrammed from CD34+ cord blood cells, matching the GMP line for preclinical development.
  • hiEX™ Research iPSC Exosomes Research-use exosomes derived from iPSCs for regenerative medicine research in wound healing, aging, and neural regeneration applications.
  • iPSC-Derived Cells Differentiated cell types including neurons, cardiomyocytes, NK cells, microglia, and retinal cells derived from iPSCs for research applications, with published unit pricing of $1,650-$3,080.
  • Genome Engineering Services Custom mammalian cell line development services using TARGATT™, CRISPR/Cas9, and MAD7 technologies for knock-in, knock-out, and point mutations, with 6-8 week turnaround for in-house lines and 2-3 months for customer-provided cells.
  • iPSC Gene Editing Services Specialized iPSC genome editing services with pluripotency maintenance, offering knock-ins, gene fusions, conditional expression, and overexpression capabilities.
  • iPSC Differentiation Services Differentiation of iPSCs into neural, hematopoietic, cardiovascular, and other lineages including neurons, NK cells, and cardiomyocytes.
  • iPSC Generation Services Reprogramming services converting somatic cells to iPSCs using episomal, Sendai virus, or retroviral methods with >95% success rate.
  • cGMP Cell Banking Services Master and working cell bank generation under GMP conditions with customizable bank size, concentration, and quality testing.
  • cGMP Cell Manufacturing Services End-to-end GMP cell therapy manufacturing including iPSC engineering, differentiation, fill-finish, and clinical drug substance production.
  • Process and Analytical Development CMC development services including gap assessment, process optimization, and analytical method qualification for cell therapy products.
  • Quality Management and Regulatory Services QA/QC and regulatory consulting for cell and gene therapy including IND/BLA preparation, FDA compliance, and ISO 13485 quality systems.

Quantifiable outcome

  • ~88% targeted integration efficiency for 50 kb constructs in iPSCs
  • +4 more outcomes

Companies that use Applied StemCell

Customer profile

Segments3 records

Ideal customer profiles2 records

Applied StemCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Applied StemCell partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cellipont BioservicescoreStrategic or Co-development Partner · 24 March 2026Strategic partnership combining Applied StemCell's GMP iPSC lines and TARGATT gene editing technology with Cellipont's cGMP manufacturing and regulatory expertise. The collaboration provides integrated iPSC-derived cell therapy development services designed to reduce technical risk and shorten development timelines by connecting upstream cell engineering with late-stage manufacturing execution. Intended to support therapy developers from early development through clinical and commercial-scale production.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Applied StemCell competitors and assessment

Company assessment

Direct peers

  • FUJIFILM Cellular Dynamics: Leading supplier of iPSC-derived differentiated cells (neurons, cardiomyocytes, hepatocytes) for drug discovery and cell therapy. Directly comparable to Applied StemCell's ActiCells and iPSC-derived cell catalog, with overlapping products, pricing models, and academic/biopharma customer base.
  • REPROCELL: Provides iPSC reprogramming services, iPSC-derived cells, and gene-editing reagents for drug discovery and regenerative medicine. Highly comparable to Applied StemCell's iPSC services and product portfolio across research and GMP-grade workflows.
  • Cellipont Bioservices: Cell therapy-focused CDMO offering cGMP manufacturing, cell banking, and regulatory services. Now an integrated partner of Applied StemCell; directly comparable for the GMP iPSC manufacturing and cell therapy CDMO services Applied StemCell delivers.
  • Takara Bio: Provides cell biology reagents, gene editing tools, and iPSC-related products including the Cellartis line. Comparable product portfolio for stem cell and gene editing research tools, serving the same academic and biopharma customers.

Emerging players

  • Century Therapeutics: Clinical-stage developer of iPSC-derived allogeneic cell therapies (NK and T cells) using multi-gene engineering. Comparable in its reliance on iPSC engineering, knock-in platforms, and hypoimmunogenic design — a downstream customer and technology benchmark for Applied StemCell.
  • Fate Therapeutics: iPSC-derived NK and T cell therapy developer using multiplexed gene editing. Comparable end-user of site-specific knock-in and large-payload integration, and a natural customer for Applied StemCell's TARGATT platform.
  • bit.bio: Developer of iPSC-derived cell products (ioCells) using opti-ox technology for reprogramming and differentiation. Comparable in offering catalog iPSC-derived cells to research and therapeutic customers, overlapping with Applied StemCell's iPSC-derived cell business.
  • Genezen: Specialty CDMO focused on lentiviral and AAV gene therapy manufacturing, with emerging cell therapy capabilities. Comparable to Applied StemCell's cGMP manufacturing services for gene-modified cell therapies, particularly in early-phase clinical supply.

Broad incumbents

  • Lonza Cell & Gene Technologies: One of the largest global CDMOs offering iPSC-derived cell therapy manufacturing, viral vector production, and process development. Overlaps with Applied StemCell's GMP iPSC and cell therapy CDMO offering as a much larger incumbent competitor.
  • Charles River Laboratories: Major CRO/CDMO with cell and gene therapy manufacturing services (via Cobra Biologics and Cellular Therapy & Innovation Center). Competes with Applied StemCell's GMP cell banking and manufacturing services as a large-scale, full-service alternative.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Applied StemCell social profiles

Digital presence

Applied StemCell compliance and trust

Trust signal

Compliance3 records

Applied StemCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Applied StemCell leadership team

Management profile

Number of profiles

Profiles12 records

Applied StemCell funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Applied StemCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Applied StemCell

What does Applied StemCell do?

Applied StemCell develops and sells proprietary genome engineering products and services centered on its TARGATT™ site-specific knock-in technology, supplemented by CRISPR/Cas9 and MAD7 platforms. The company manufactures and distributes TARGATT™ knock-in kits (RUO and GMP grades), ActiCells™ iPSC lines, iPSC-derived differentiated cells, and hiEX™ research exosomes, and provides custom cell line engineering, iPSC generation/editing/differentiation, and cGMP cell banking and manufacturing services to biopharma and academic customers.

Is Applied StemCell a public or private company?

Applied StemCell is a private company. It is classified as venture growth investor backed and is currently operating.

When was Applied StemCell founded?

Applied StemCell was founded in 2008. It employs 11 to 50 people.

Where is Applied StemCell based?

Applied StemCell is headquartered in Milpitas, United States, in the North America region.

How does Applied StemCell make money?

Five revenue lines are on record. TARGATT Knock-in Kits are the primary driver. The others are iPSC Products, genome Engineering Services, iPSC Services and cGMP Manufacturing Services.

Who are Applied StemCell's main competitors?

Direct peers on record are FUJIFILM Cellular Dynamics, REPROCELL, Cellipont Bioservices and Takara Bio. Emerging players are Century Therapeutics, Fate Therapeutics, bit.bio and Genezen. Broad incumbents are Lonza Cell & Gene Technologies and Charles River Laboratories.

Does Applied StemCell have an API?

No public API is recorded for Applied StemCell.

What industry is Applied StemCell in?

Applied StemCell's product category is Cell therapy and genome engineering services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerStem cells market to cross USD 32.57BThe global stem cells market is projected to grow from USD 18.9 billion in 2026 to USD 32.57 billion by 2031, a CAGR of 11.5%. Growth is driven by regenerative medicine interest and aging populations, with North America leading and Asia-Pacific expanding fastest. Recent partnerships include Applied StemCell and Cellipont, and Aspect Biosystems and Novo Nordisk.PR NewswireStem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen ResearchThe global stem cells market is projected to grow from USD 18.9 billion in 2026 to USD 32.57 billion by 2031, a CAGR of 11.5%, driven by regenerative medicine and cell-based therapies. Adult stem cells led product revenue in 2025, and North America held the largest regional share. Asia-Pacific is the fastest-growing region.AijournRoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess SolutionsApplied StemCell and RoosterBio announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions for advanced therapy developers. The collaboration combines ASC's GMP-compatible induced pluripotent stem cell technology with RoosterBio's engineered media systems and scalable manufacturing expertise into an integrated end-to-end solution. The partnership aims to reduce complexity, accelerate timelines, and support the growing global demand for scalable, high-quality iPSC-based products across immunotherapy, neurodegenerative disease, and other therapeutic applications.PR NewswireRoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess SolutionsApplied StemCell and RoosterBio announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions for advanced therapies, combining ASC's GMP-compatible induced pluripotent stem cell technology with RoosterBio's engineered media systems and scalable manufacturing expertise. The collaboration aims to provide therapeutic developers with an integrated end-to-end solution that reduces complexity, improves consistency, and accelerates timelines from early research through clinical manufacturing. The partnership addresses long-standing consistency and quality gaps that have limited iPSC developers by offering a unified system complete with bioprocess media, GMP-sourced iPSCs, and manufacturing processes designed for clinical and commercial scale production.GenengnewsExpanding the Toolbox for Mammalian Genome EngineeringApplied StemCell published sponsored content describing their TARGATT technology, which addresses the challenge of integrating large DNA payloads into mammalian genomes by combining efficient site-specific integration using a large serine recombinase with a validated H11 safe harbor locus target site. The technology enables single-copy, defined genomic integration of multi-gene constructs and full-length genes without relying on cellular repair pathways, reducing clonal variability and screening burden compared to conventional homology-directed repair and random integration approaches. This platform is positioned for applications in cell therapy development, biomanufacturing, and synthetic biology.BioSpaceApplied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy DevelopmentApplied StemCell and Cellipont Bioservices announced a strategic partnership to provide integrated iPSC-derived cell therapy development services, combining ASC's GMP iPSC lines and TARGATT™ gene editing technology with Cellipont's cGMP manufacturing and regulatory expertise. The collaboration aims to reduce technical risk and shorten development timelines by connecting upstream cell engineering with late-stage manufacturing execution. This integrated pathway is designed to support therapy developers moving from early development through clinical and commercial-scale production.GlobeNewswireApplied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy DevelopmentApplied StemCell and Cellipont Bioservices announced a strategic partnership to streamline and accelerate iPSC-derived cell therapy development. The collaboration connects ASC's iPSC engineering technology and GMP cell banking services with Cellipont's cGMP manufacturing and regulatory support capabilities. The companies stated the partnership is designed to reduce technical risk, shorten development timelines, and support progression from early development through clinical and commercial-scale production.GlobeNewswireApplied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ TechnologyApplied StemCell announced the successful site-specific integration of a 50 kb DNA construct into human induced pluripotent stem cells using its proprietary TARGATT™ technology, achieving greater than 20% efficiency at the H11 safe harbor locus. The 50 kb multifunctional construct, produced by Ansa Biotechnologies using enzymatic DNA synthesis, contains multiple expression cassettes enabling immune evasion and tunable gene expression with virtually 100% constitutive transgene expression. This milestone enables new applications in allogeneic cell therapy development, multi-protein complex expression, and stable viral vector manufacturing.GlobeNewswireApplied StemCell Appoints Dolores Baksh, Ph.D., as Chief Executive OfficerApplied StemCell appointed Dolores Baksh as CEO, with founder Ruby Tsai continuing as President and CSO. Baksh brings over 20 years of life sciences leadership, including prior roles at Hyperius Biotech and TAAV Biomanufacturing Solutions. The company aims to expand commercial reach and accelerate new product development.